Last reviewed 2026-05-14 · How we verify

GSK Biologicals'Kinrix®

Kinrix is a combination vaccine that provides immunization against diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B by stimulating the immune system to produce protective antibodies against these pathogens.

Kinrix is a combination vaccine that provides immunization against diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B by stimulating the immune system to produce protective antibodies against these pathogens. Used for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B in infants and children (ages 6 weeks to 6 years).

At a glance

Mechanism of action

Kinrix combines five inactivated vaccines (DTaP-IPV-HepB) in a single injection. It works by introducing inactivated or recombinant antigens from these five diseases, which trigger both humoral and cellular immune responses. This results in the production of specific antibodies and memory immune cells that protect against infection if exposure occurs.

Approved indications

• Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B in infants and children (ages 6 weeks to 6 years)

Common side effects

• Injection site pain, redness, or swelling
• Fever
• Irritability or fussiness
• Drowsiness
• Loss of appetite

Key clinical trials

• Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• GSK Biologicals'Kinrix® CI brief — competitive landscape report
• GSK Biologicals'Kinrix® updates RSS · CI watch RSS
• GlaxoSmithKline portfolio CI